Dr. Barry Dworkin

Phase 1 targeted gene editing study demonstrates safety and reduction in LDL cholesterol levels through specific protein pathway

Medical Mythbusting Commentary for August 17, 2026

Source:
‘An extremely exciting milestone!’: landmark treatment slashes cholesterol by 62% with a single dose

Reference:
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia

Related posts:

  1. Genetic switch may help heal heart after heart attack but application is years away
  2. Barley barely has a clinical impact on lowering “bad cholesterol” despite study headlines to the contrary
  3. Study that suggests LDL (bad) cholesterol does not casue heart disease is an example of cherry-picking the evidence and flawed design
  4. Genes research offers cancer treatment hope